David E J Jones
Overview
Explore the profile of David E J Jones including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
123
Citations
2394
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leighton J, Jones D, Dyson J, Cordell H
BMC Med Genomics
. 2024 Jun;
17(1):157.
PMID: 38862968
Primary Sclerosing Cholangitis (PSC) is a progressive cholestatic liver disease with no licensed therapies. Previous Genome Wide Association Studies (GWAS) have identified genes that correlate significantly with PSC, and these...
2.
Jones D, Beuers U, Bonder A, Carbone M, Culver E, Dyson J, et al.
Hepatology
. 2024 Mar;
80(5):1291-1300.
PMID: 38506926
Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease. The management landscape was transformed 20 years ago with the advent of ursodeoxycholic acid. Up to 40% of patients do...
3.
Arenas Y, Izquierdo-Altarejos P, Martinez-Garcia M, Gimenez-Garzo C, Mincheva G, Doverskog M, et al.
Liver Int
. 2023 Nov;
44(2):433-445.
PMID: 38010893
Background And Aims: Many patients with the chronic cholestatic liver disease primary biliary cholangitis (PBC) show fatigue and cognitive impairment that reduces their quality of life. Likewise, rats with bile...
4.
Mayo M, Vierling J, Bowlus C, Levy C, Hirschfield G, Neff G, et al.
Aliment Pharmacol Ther
. 2023 Oct;
59(2):186-200.
PMID: 37904314
Background: Seladelpar is a potent and selective peroxisome proliferator-activated receptor-δ agonist that targets multiple cell types involved in primary biliary cholangitis (PBC), leading to anti-cholestatic, anti-inflammatory and anti-pruritic effects. Aims:...
5.
Hirschfield G, Shiffman M, Gulamhusein A, Kowdley K, Vierling J, Levy C, et al.
Hepatology
. 2023 Jun;
78(2):397-415.
PMID: 37386786
Background And Aims: ENHANCE was a phase 3 study that evaluated efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor-δ (PPAR) agonist, versus placebo in patients with primary biliary...
6.
Wetten A, Ogle L, Mells G, Hegade V, Jopson L, Corrigan M, et al.
Can J Gastroenterol Hepatol
. 2022 Dec;
2022:3618090.
PMID: 36523650
Background And Aims: A third of patients with primary biliary cholangitis (PBC) experience poorly understood cognitive symptoms, with a significant impact on quality of life (QOL), and no effective medical...
7.
Gee L, Barron-Millar B, Leslie J, Richardson C, Zaki M, Luli S, et al.
Am J Pathol
. 2022 Oct;
193(1):11-26.
PMID: 36243043
Patients with cholestatic liver disease, including those with primary biliary cholangitis, can experience symptoms of impaired cognition or brain fog. This phenomenon remains unexplained and is currently untreatable. Bile duct...
8.
Jones D, Wetten A, Barron-Millar B, Ogle L, Mells G, Flack S, et al.
EBioMedicine
. 2022 May;
80:104068.
PMID: 35609437
Background: Uncertainty exists about how best to identify primary biliary cholangitis (PBC) patients who would benefit from second-line therapy. Existing, purely clinical, ursodeoxycholic acid (UDCA) response criteria accept degrees of...
9.
Lloyd C, Leighton J, Wong L, Goulding A, Brownlee A, Gray P, et al.
Dig Dis Sci
. 2022 May;
68(1):87-97.
PMID: 35579795
Background: Data show that patients with autoimmune hepatitis have significantly reduced quality-of-life and that corticosteroids carry marked side effects. Aims: This study explored patients' experiences of autoimmune hepatitis and its...
10.
Bowlus C, Galambos M, Aspinall R, Hirschfield G, Jones D, Dorffel Y, et al.
J Hepatol
. 2022 Apr;
77(2):353-364.
PMID: 35367282
Background & Aims: We examined the efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor-delta agonist, in adults with primary biliary cholangitis (PBC) at risk of disease progression (alkaline...